REFERENCES
- MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke and coronary heart disease. Part I: Effectsof prolonged differences in blood pressure - evidence from nine prospectiveobservational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774
- Colhoun H. M., Dong W., Poulter N. R. Blood pressure screening, management and control in England:results from the Health Survey for England 1994. J Hypertens 1998; 16: 747–752
- Burt V. L., Whelton P., Roccella E. J., et al. Prevalence of hypertension in the US adult population. Resultsfrom the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313
- Marques-Vidal P., Tuomilehto J. Hypertension awareness, treatment and control in the community:is the ‘rule of halves’ still valid?. J Hum Hypertens 1997; 11: 213–220
- Hansson L., Zanchetti A., Carruthers S. G., et al. for the HOT Study Group. Effects of intensive blood-pressurelowering and low-dose aspirin in patients with hypertension: principal resultsof the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762
- Guidelines Subcommittee. 1999 World Health Organization-InternationalSociety of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–183
- Materson B. J., Reda D. J., Cushman W. C. Department of Veterans Affairs single-drug therapy of hypertensionstudy. Revised figures and new data. Department of Veterans Affairs CooperativeStudy Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189–192
- Neutel J. M., Black H. R., Weber M. A. Combination therapy with diuretics: an evolution of understanding. Am J Med 1996; 101: 61S–70S
- Moser M., Black H. R. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998; 11: 73S–78S
- Sever P. S. Additional therapy versus monotherapy in the treatment of hypertension. Br J Cardiol 1999; 6: 24–34
- Ménard J. Critical assessment of combination therapy development. BloodPress. 1993; 2(Suppl 1)5–9
- Heuer H. J., Schöndorfer G., Högemann A. M. Twenty-four hour blood pressure profile of different doses ofcandesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11(Suppl 2)S55–S56
- Morsing P., Adler G., Brandt-Eliasson U., et al. Mechanistic differences of various AT1-receptor blockers inisolated vessels of different origin. Hypertension 1999; 33: 1406–1413
- Mazzolai L., Burnier M. Comparative safety and tolerability of angiotensin II receptorantagonists. Drug Safety 1999; 21: 23–33
- Ruilope L. M., Simpson R. L., Toh J., Arcuri K. E., Goldberg A. I., Sweet C. S. Controlled trial of losartan given concomitantly with differentdoses of hydrochlorothiazide in hypertensive patients. Blood Press. 1996; 5: 32–40
- Simpson R. L. Efficacy and safety of losartan (L) combined with hydrochlorothiazide(H) in patients with mild to severe hypertension. Am J Hypertens 1994; 4: A18
- Soffer B. A., Wright J. T., Jr, Pratt J. H., Wiens B., Goldberg A. I., Sweet C. S. Effects of losartan on a background of hydrochlorothiazide inpatients with hypertension. Hypertension 1995; 26: 112–117
- Grossman E., Peleg E., Carroll J., Shamiss A., Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonistlosartan in essential hypertension. Am J Hypertens 1994; 7: 1041–1044
- Plouin P.-F. Combination therapy with candesartan cilexetil plus hydrochlorothiazidein patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997; 11(Suppl 2)S65–S66
- Oparil S., Levine J. H., Zuschke C. A., Gradman A. H., Ripley E., Jones D. W. Effects of candesartan cilexetil in patients with severe systemichypertension. Am J Cardiol 1999; 84: 289–293
- Elmfeldt D., George M., Hübner R., Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist,provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11(Suppl 2)S49–S53
- Philipp T., Letzel H., Arens H.-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazidein patients with mild to moderate hypertension. J Hum Hypertens 1997; 11(Suppl 2)S67–S68
- Iacono P., Drici M. D., De Lunardo C., Salimbeni B., Lapalus P. Placebo effect in cardiovascular clinical pharmacology. Int J Clin Pharmacol Res 1992; 12: 53–56
- Manual of Hypertension, J D Swales. Oxford:Blackwell Science Ltd. 1995
- Sever P. S., Michel J., Voet B. Candesartan cilexetil (CC): a meta-analysis of time-to-effectrelationship. Am J Hypertens 1998; 11: 79
- McInnes G. T., Yeo W. W., Ramsay L. E., Moser M. Cardiotoxicity of diuretics: much speculation - little substance. J Hypertens 1992; 10: 317–335